Share to:

 

Κ-opioid receptor

OPRK1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesOPRK1, K-OR-1, KOR, KOR-1, OPRK, opioid receptor kappa 1, KOR1, KOP
External IDsOMIM: 165196; MGI: 97439; HomoloGene: 20253; GeneCards: OPRK1; OMA:OPRK1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4986

18387

Ensembl

ENSG00000082556

ENSMUSG00000025905

UniProt

P41145

P33534

RefSeq (mRNA)

NM_001282904
NM_000912
NM_001318497

NM_001204371
NM_011011
NM_001318735

RefSeq (protein)

NP_000903
NP_001269833
NP_001305426

NP_001191300
NP_001305664
NP_035141

Location (UCSC)Chr 8: 53.23 – 53.25 MbChr 1: 5.66 – 5.68 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

The κ-opioid receptor or kappa opioid receptor, abbreviated KOR or KOP for its ligand ketazocine, is a G protein-coupled receptor that in humans is encoded by the OPRK1 gene. The KOR is coupled to the G protein Gi/G0 and is one of four related receptors that bind opioid-like compounds in the brain and are responsible for mediating the effects of these compounds. These effects include altering nociception, consciousness, motor control, and mood. Dysregulation of this receptor system has been implicated in alcohol and drug addiction.[5][6]

The KOR is a type of opioid receptor that binds the opioid peptide dynorphin as the primary endogenous ligand (substrate naturally occurring in the body).[7] In addition to dynorphin, a variety of natural alkaloids, terpenes and synthetic ligands bind to the receptor. The KOR may provide a natural addiction control mechanism, and therefore, drugs that target this receptor may have therapeutic potential in the treatment of addiction [citation needed].

There is evidence that distribution and/or function of this receptor may differ between sexes.[8][9][10][11]

Distribution

KORs are widely distributed in the brain, spinal cord (substantia gelatinosa), and in peripheral tissues. High levels of the receptor have been detected in the prefrontal cortex, periaqueductal gray, raphe nuclei (dorsal), ventral tegmental area, substantia nigra, dorsal striatum (putamen, caudate), ventral striatum (nucleus accumbens, olfactory tubercle), amygdala, bed nucleus stria terminalis, claustrum, hippocampus, hypothalamus, midline thalamic nuclei, locus coeruleus, spinal trigeminal nucleus, parabrachial nucleus, and solitary nucleus.[12][13]

Subtypes

Based on receptor binding studies, three variants of the KOR designated κ1, κ2, and κ3 have been characterized.[14][15] However, only one cDNA clone has been identified,[16] hence these receptor subtypes likely arise from interaction of one KOR protein with other membrane associated proteins.[17]

Function

Pain

Similarly to μ-opioid receptor (MOR) agonists, KOR agonists are potently analgesic, and have been employed clinically in the treatment of pain. However, KOR agonists also produce side effects such as dysphoria, hallucinations, and dissociation, which has limited their clinical usefulness.[18] Examples of KOR agonists that have been used medically as analgesics include butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, and eptazocine. Difelikefalin (CR845, FE-202845) and CR665 (FE-200665, JNJ-38488502) are peripherally restricted KOR agonists lacking the CNS side effects of centrally active KOR agonists and are currently under clinical investigation as analgesics.

Consciousness

Centrally active KOR agonists have hallucinogenic or dissociative effects, as exemplified by salvinorin A (the active constituent in Salvia divinorum). These effects are generally undesirable in medicinal drugs. It is thought that the hallucinogenic and dysphoric effects of opioids such as butorphanol, nalbuphine, and pentazocine serve to limit their abuse potential. In the case of salvinorin A, a structurally novel neoclerodane diterpene KOR agonist, these hallucinogenic effects are sought by recreational users, despite the dysphoria experienced by some users. Another KOR agonist with comparable effects is ibogaine, which has possible medical application in addiction treatment. While these KOR agonists possess hallucinogenic and dissociative effects, they are mechanistically and qualitatively different from those of the 5HT2AR agonist psychedelic hallucinogens such as lysergic acid diethylamide (LSD) or psilocybin and those of NMDAR antagonist dissociatives/anesthetics ketamine and phencyclidine.[19]

The claustrum is the region of the brain in which the KOR is most densely expressed.[20][21][22] It has been proposed that this area, based on its structure and connectivity, has "a role in coordinating a set of diverse brain functions", and the claustrum has been elucidated as playing a crucial role in consciousness.[21][22] As examples, lesions of the claustrum in humans are associated with disruption of consciousness and cognition, and electrical stimulation of the area between the insula and the claustrum has been found to produce an immediate loss of consciousness in humans along with recovery of consciousness upon cessation of the stimulation.[22][23] On the basis of the preceding knowledge, it has been proposed that inhibition of the claustrum (as well as, "additionally, the deep layers of the cortex, mainly in prefrontal areas") by activation of KORs in these areas is primarily responsible for the profound consciousness-altering/dissociative hallucinogen effects of salvinorin A and other KOR agonists.[21][22] In addition, it has been stated that "the subjective effects of S. divinorum indicate that salvia disrupts certain facets of consciousness much more than the largely serotonergic hallucinogen [LSD]", and it has been postulated that inhibition of a brain area that is apparently as fundamentally involved in consciousness and higher cognitive function as the claustrum may explain this.[21] However, these conclusions are merely tentative, as "[KORs] are not exclusive to the claustrum; there is also a fairly high density of receptors located in the prefrontal cortex, hippocampus, nucleus accumbens and putamen", and "disruptions to other brain regions could also explain the consciousness-altering effects [of salvinorin A]".[22]

In supplementation of the above, according to Addy et al.:[20]

Theories suggest the claustrum may act to bind and integrate multisensory information, or else to encode sensory stimuli as salient or nonsalient (Mathur, 2014). One theory suggests the claustrum harmonizes and coordinates activity in various parts of the cortex, leading to the seamless integrated nature of subjective conscious experience (Crick and Koch, 2005; Stiefel et al., 2014). Disrupting claustral activity may lead to conscious experiences of disintegrated or unusually bound sensory information, perhaps including synesthesia. Such theories are in part corroborated by the fact that [salvia divinorum], which functions almost exclusively on the KOR system, can cause consciousness to be decoupled from external sensory input, leading to experiencing other environments and locations, perceiving other "beings" besides those actually in the room, and forgetting oneself and one's body in the experience.[20]

Mood, stress, and addiction

See also: κ-opioid receptor § Role in treatment of drug addiction

The involvement of the KOR in stress, as well as in consequences of chronic stress such as depression, anxiety, anhedonia, and increased drug-seeking behavior, has been made clear.[18] KOR agonists are notably dysphoric and aversive at sufficient doses.[24] The KOR antagonists buprenorphine, as ALKS-5461 (a combination formulation with samidorphan), and aticaprant (LY-2456302, CERC-501) are currently in clinical development for the treatment of major depressive disorder and substance use disorders.[25] JDTic and PF-4455242 were also under investigation but development was halted in both cases due to toxicity concerns.[25]

The depressive-like behaviors following prolonged morphine abstinence appear to be mediated by upregulation of the KOR/dynorphin system in the nucleus accumbens, as the local application of a KOR antagonist prevented the behaviors.[26] As such, KOR antagonists might be useful for the treatment of depressive symptoms associated with opioid withdrawal.[26]

In a small clinical study, pentazocine, a KOR agonist, was found to rapidly and substantially reduce symptoms of mania in patients with bipolar disorder.[8] It was postulated that the efficacy observed was due to KOR activation-mediated amelioration of excessive dopaminergic signaling in the reward pathways.[8][failed verification]

Others

A variety of other effects of KOR activation are known:

  • Activation of the KOR appears to antagonize many of the effects of the MOR, including analgesia, tolerance, euphoria, and memory regulation.[27] Nalorphine and nalmefene are dual MOR antagonists and KOR agonists that have been used clinically as antidotes for opioid overdose, although the specific role and significance of KOR activation in this indication, if any, is uncertain. In any case however, KOR agonists notably do not affect respiratory drive, and hence do not reverse MOR activation-induced respiratory depression.[28]
  • KOR agonists suppress itching, and the selective KOR agonist nalfurafine is used clinically as an antipruritic (anti-itch drug).
  • Eluxadoline is a peripherally restricted KOR agonist as well as MOR agonist and DOR antagonist that has been approved for the treatment of diarrhea-predominant irritable bowel syndrome. Asimadoline and fedotozine are selective and similarly peripherally restricted KOR agonists that were also investigated for the treatment of irritable bowel syndrome and reportedly demonstrated at least some efficacy for this indication but were ultimately never marketed.
  • KOR agonists are known for their characteristic diuretic effects, due to their negative regulation of vasopressin, also known as antidiuretic hormone (ADH).[29]
  • KOR agonism is neuroprotective against hypoxia/ischemia.[30]
  • The selective KOR agonist U-50488 protected rats against supramaximal electroshock seizures, indicating that KOR agonism may have anticonvulsant effects.[31]

Signal transduction

KOR activation by agonists is coupled to the G protein Gi/G0, which subsequently increases phosphodiesterase activity. Phosphodiesterases break down cAMP, producing an inhibitory effect in neurons.[32][33][34] KORs also couple to inward-rectifier potassium[35] and to N-type calcium ion channels.[36] Recent studies have also demonstrated that agonist-induced stimulation of the KOR, like other G-protein coupled receptors, can result in the activation of mitogen-activated protein kinases (MAPK). These include extracellular signal-regulated kinase, p38 mitogen-activated protein kinases, and c-Jun N-terminal kinases.[37][38][39][40][41][42]

Ligands

22-Thiocyanatosalvinorin A (RB-64) is a functionally-selective κ-opioid receptor agonist.

Agonists

The synthetic alkaloid ketazocine[43] and terpenoid natural product salvinorin A[19] are potent and selective KOR agonists. The KOR also mediates the dysphoria and hallucinations seen with opioids such as pentazocine.[44]

Benzomorphans
Morphinans
Arylacetamides
Peptides (endo-/exogenous)
Terpenoids
Others/unsorted

Nalfurafine (Remitch), which was introduced in 2009, is the first selective KOR agonist to enter clinical use.[50][51]

Antagonists

Natural agonists

Mentha spp.

Main article: menthol

Found in numerous species of mint, (including peppermint, spearmint, and watermint), the naturally-occurring compound menthol is a weak KOR agonist[56] owing to its antinociceptive, or pain blocking, effects in rats. In addition, mints can desensitize a region through the activation of TRPM8 receptors (the 'cold'/menthol receptor).[57]

Salvia divinorum

Main article: Salvia divinorum

The key compound in Salvia divinorum, salvinorin A, is known as a powerful, short-acting KOR agonist.[19][58][59]

Ibogaine

Main article: ibogaine

Used for the treatment of addiction in limited countries, ibogaine has become an icon of addiction management among certain underground circles. Despite its lack of addictive properties, ibogaine is listed as a Schedule I compound in the US because it is a psychoactive substance, hence it is considered illegal to possess under any circumstances. Ibogaine is also a KOR agonist[60] and this property may contribute to the drug's anti-addictive efficacy.[61]

Mitragyna speciosa

Main article: Mitragyna speciosa

Allosteric modulators

Positive allosteric modulators

Role in treatment of drug addiction

KOR agonists have been investigated for their therapeutic potential in the treatment of addiction[64] and evidence points towards dynorphin, the endogenous KOR agonist, to be the body's natural addiction control mechanism.[65] Childhood stress/abuse is a well known predictor of drug abuse and is reflected in alterations of the MOR and KOR systems.[66] In experimental "addiction" models the KOR has also been shown to influence stress-induced relapse to drug seeking behavior. For the drug-dependent individual, risk of relapse is a major obstacle to becoming drug-free. Recent reports demonstrated that KORs are required for stress-induced reinstatement of cocaine seeking.[67][68]

One area of the brain most strongly associated with addiction is the nucleus accumbens (NAcc) and striatum while other structures that project to and from the NAcc also play a critical role. Though many other changes occur, addiction is often characterized by the reduction of dopamine D2 receptors in the NAcc.[69] In addition to low NAcc D2 binding,[70][71] cocaine is also known to produce a variety of changes to the primate brain such as increases prodynorphin mRNA in caudate putamen (striatum) and decreases of the same in the hypothalamus while the administration of a KOR agonist produced an opposite effect causing an increase in D2 receptors in the NAcc.[72]

Additionally, while cocaine overdose victims showed a large increase in KORs (doubled) in the NAcc,[73] KOR agonist administration is shown to be effective in decreasing cocaine seeking and self-administration.[74] Furthermore, while cocaine abuse is associated with lowered prolactin response,[75] KOR activation causes a release in prolactin,[76] a hormone known for its important role in learning, neuronal plasticity and myelination.[77]

It has also been reported that the KOR system is critical for stress-induced drug-seeking. In animal models, stress has been demonstrated to potentiate cocaine reward behavior in a kappa opioid-dependent manner.[78][79] These effects are likely caused by stress-induced drug craving that requires activation of the KOR system. Although seemingly paradoxical, it is well known that drug taking results in a change from homeostasis to allostasis. It has been suggested that withdrawal-induced dysphoria or stress-induced dysphoria may act as a driving force by which the individual seeks alleviation via drug taking.[80] The rewarding properties of drug are altered, and it is clear KOR activation following stress modulates the valence of drug to increase its rewarding properties and cause potentiation of reward behavior, or reinstatement to drug seeking. The stress-induced activation of KORs is likely due to multiple signaling mechanisms. The effects of KOR agonism on dopamine systems are well documented, and recent work also implicates the mitogen-activated protein kinase cascade and pCREB in KOR-dependent behaviors.[40][81]

While the predominant drugs of abuse examined have been cocaine (44%), ethanol (35%), and opioids (24%).[82] As these are different classes of drugs of abuse working through different receptors (increasing dopamine directly and indirectly, respectively) albeit in the same systems produce functionally different responses. Conceptually then pharmacological activation of KOR can have marked effects in any of the psychiatric disorders (depression, bipolar disorder, anxiety, etc.) as well as various neurological disorders (i.e. Parkinson's disease and Huntington's disease).[6][83] Not only are genetic differences in dynorphin receptor expression a marker for alcohol dependence but a single dose of a KOR antagonist markedly increased alcohol consumption in lab animals.[84] There are numerous studies that reflect a reduction in self-administration of alcohol,[85] and heroin dependence has also been shown to be effectively treated with KOR agonism by reducing the immediate rewarding effects[86] and by causing the curative effect of up-regulation (increased production) of MORs[87] that have been down-regulated during opioid abuse.

The anti-rewarding properties of KOR agonists are mediated through both long-term and short-term effects. The immediate effect of KOR agonism leads to reduction of dopamine release in the NAcc during self-administration of cocaine[88] and over the long term up-regulates receptors that have been down-regulated during substance abuse such as the MOR and the D2 receptor. These receptors modulate the release of other neurochemicals such as serotonin in the case of MOR agonists and acetylcholine in the case of D2. These changes can account for the physical and psychological remission of the pathology of addiction. The longer effects of KOR agonism (30 minutes or greater) have been linked to KOR-dependent stress-induced potentiation and reinstatement of drug seeking. It is hypothesized that these behaviors are mediated by KOR-dependent modulation of dopamine, serotonin, or norepinephrine and/or via activation of downstream signal transduction pathways.

Of significant note, while KOR activation blocks many of the behavioral and neurochemical responses elicited by drugs of abuse as stated above. These results are indicative of the KOR induced negative affective states counteracting the rewarding effects of drugs of abuse. Implicating the KOR/dynorphin system as an anti-reward system, supported by the role of KOR signaling and stress, mediating both stress-induced potentiation of drug reward and stress-induced reinstatement of seeking behavior.[6][83] This in turn addresses what was thought to be paradoxical above. That is, rather, KOR signaling is activated/upregulated by stress, drugs of abuse and agonist administration - resulting in negative affective state. As such drug addiction is maintained by avoidance of negative affective states manifest in stress, craving, and drug withdrawal.[89] Consistent with KOR induced negative affective states and role in drug addiction, KOR antagonists are efficacious at blocking negative affect induced by drug withdrawal and at decreasing escalated drug intake in pre-clinical trial involving extended drug access.[6][83][82] Clinically there has been little advancement to evaluate the effects of KOR antagonists due to adverse effects and undesirable pharmacological profiles for clinical testing (i.e. long half-life, poor bioavailability). More recently, a selective, high-affinity KOR antagonist LY2456302 was well-tolerated in CUD patients.[90] Showing feasibility a subsequent proof-of-mechanism trial evaluated JNJ-67953964 (previously LY2456302) potential for treating anhedonia in a double-blind, placebo-controlled, randomized trial in patients with anhedonia and a mood or anxiety disorder.[91] The KOR antagonist significantly increased fMRI ventral striatum activation during reward anticipation while accompanied by therapeutic effects on clinical measures of anhedonia, further reinforces the promise of KOR antagonism and proceeding assessment of clinical impact.[91] Additionally a positron emission tomography (PET) study in cocaine use disorder (CUD) patients utilizing a KOR selective agonist [11C]GR103545 radioligand showed CUD individuals with higher KOR availability were more prone to stress-induced relapse.[92] A subsequent PET scan following a three-day cocaine binge showed a decrease in KOR availability, interpreted as increased endogenous dynorphin competing with the radioligand at the KOR binding sites.[92] Taken together these findings are in support of the negative affect state and further implicate the KOR/dynorphin system clinically and therapeutically relevant in humans with CUD. Taken together, in drug addiction the KOR/dynorphin system is implicated as a homeostatic mechanism to counteract the acute effects of drugs of abuse. Chronic drug use and stress up-regulate the system in turn leading to a dysregulated state which induces negative affective states and stress reactivity.[83]

Traditional models of KOR function in drug addiction have postulated that KOR signaling is associated with dysphoria and aversion, thought to underlie the stress-induced exacerbation of addiction. However, recent research in animal models has proposed alternative models, suggesting that KOR-mediated responses may not act directly on negative valence systems but modulate related processes such as novelty processing.[93][94] Studies in humans same to similar conclusions that KORs may modulate various aspects of reward processing in a manner that is independent of the hedonic valence traditionally ascribed to them.[95][96] This broadens the potential understanding of KORs in addiction beyond a unidimensional framework, implicating their role in complex behaviors and treatment approaches that do not align strictly with stress or aversion. These emerging perspectives may inform the development of novel pharmacotherapies targeting KORs for the treatment of substance use disorders, as they highlight the receptor's multifaceted role in addiction.

Interactions

KOR has been shown to interact with sodium-hydrogen antiporter 3 regulator 1,[97][98] ubiquitin C,[99] 5-HT1A receptor,[100] and RGS12.[101]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000082556 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025905 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Anderson RI, Becker HC (August 2017). "Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol". Alcoholism: Clinical and Experimental Research. 41 (8): 1402–1418. doi:10.1111/acer.13406. PMC 5522623. PMID 28425121.
  6. ^ a b c d Karkhanis A, Holleran KM, Jones SR (2017). "Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction". International Review of Neurobiology. 136: 53–88. doi:10.1016/bs.irn.2017.08.001. ISBN 9780128124734. PMID 29056156.
  7. ^ James IF, Chavkin C, Goldstein A (1982). "Selectivity of dynorphin for kappa opioid receptors". Life Sciences. 31 (12–13): 1331–4. doi:10.1016/0024-3205(82)90374-5. PMID 6128656.
  8. ^ a b c Chartoff EH, Mavrikaki M (2015). "Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction". Frontiers in Neuroscience. 9: 466. doi:10.3389/fnins.2015.00466. PMC 4679873. PMID 26733781.
  9. ^ Rasakham K, Liu-Chen LY (January 2011). "Sex differences in kappa opioid pharmacology". Life Sciences. 88 (1–2): 2–16. doi:10.1016/j.lfs.2010.10.007. PMC 3870184. PMID 20951148.
  10. ^ Siciliano CA, Calipari ES, Yorgason JT, Lovinger DM, Mateo Y, Jimenez VA, Helms CM, Grant KA, Jones SR (April 2016). "Increased presynaptic regulation of dopamine neurotransmission in the nucleus accumbens core following chronic ethanol self-administration in female macaques". Psychopharmacology. 233 (8): 1435–43. doi:10.1007/s00213-016-4239-4. PMC 4814331. PMID 26892380.
  11. ^ Johnson BN, Kumar A, Su Y, Singh S, Sai KK, Nader SH, et al. (September 2022). "PET imaging of kappa opioid receptors and receptor expression quantified in neuron-derived extracellular vesicles in socially housed female and male cynomolgus macaques". Neuropsychopharmacology. 48 (2): 410–417. doi:10.1038/s41386-022-01444-9. PMC 9751296. PMID 36100655.
  12. ^ Wang YH, Sun JF, Tao YM, Chi ZQ, Liu JG (September 2010). "The role of kappa-opioid receptor activation in mediating antinociception and addiction". Acta Pharmacologica Sinica. 31 (9): 1065–70. doi:10.1038/aps.2010.138. PMC 4002313. PMID 20729876.
  13. ^ Mansour A, Fox CA, Akil H, Watson SJ (January 1995). "Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications". Trends in Neurosciences. 18 (1): 22–9. doi:10.1016/0166-2236(95)93946-U. PMID 7535487. S2CID 300974.
  14. ^ de Costa BR, Rothman RB, Bykov V, Jacobson AE, Rice KC (February 1989). "Selective and enantiospecific acylation of kappa opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexy l] benzeneacetamide. Demonstration of kappa receptor heterogeneity". Journal of Medicinal Chemistry. 32 (2): 281–3. doi:10.1021/jm00122a001. PMID 2536435.
  15. ^ Rothman RB, France CP, Bykov V, De Costa BR, Jacobson AE, Woods JH, Rice KC (August 1989). "Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes" (PDF). European Journal of Pharmacology. 167 (3): 345–53. doi:10.1016/0014-2999(89)90443-3. hdl:2027.42/27799. PMID 2553442.
  16. ^ Mansson E, Bare L, Yang D (August 1994). "Isolation of a human kappa opioid receptor cDNA from placenta". Biochemical and Biophysical Research Communications. 202 (3): 1431–7. doi:10.1006/bbrc.1994.2091. PMID 8060324.
  17. ^ Jordan BA, Devi LA (June 1999). "G-protein-coupled receptor heterodimerization modulates receptor function". Nature. 399 (6737): 697–700. Bibcode:1999Natur.399..697J. doi:10.1038/21441. PMC 3125690. PMID 10385123.
  18. ^ a b Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (January 2008). "The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system". The Journal of Neuroscience. 28 (2): 407–14. doi:10.1523/JNEUROSCI.4458-07.2008. PMC 2612708. PMID 18184783.
  19. ^ a b c Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (September 2002). "Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist". Proceedings of the National Academy of Sciences of the United States of America. 99 (18): 11934–9. Bibcode:2002PNAS...9911934R. doi:10.1073/pnas.182234399. PMC 129372. PMID 12192085.
  20. ^ a b c Addy PH, Garcia-Romeu A, Metzger M, Wade J (April 2015). "The subjective experience of acute, experimentally-induced Salvia divinorum inebriation". Journal of Psychopharmacology. 29 (4): 426–35. doi:10.1177/0269881115570081. PMID 25691501. S2CID 34171297.
  21. ^ a b c d Stiefel KM, Merrifield A, Holcombe AO (2014). "The claustrum's proposed role in consciousness is supported by the effect and target localization of Salvia divinorum". Frontiers in Integrative Neuroscience. 8: 20. doi:10.3389/fnint.2014.00020. PMC 3935397. PMID 24624064.
  22. ^ a b c d e Chau A, Salazar AM, Krueger F, Cristofori I, Grafman J (November 2015). "The effect of claustrum lesions on human consciousness and recovery of function". Consciousness and Cognition. 36: 256–64. doi:10.1016/j.concog.2015.06.017. PMID 26186439. S2CID 46139982.
  23. ^ Koubeissi MZ, Bartolomei F, Beltagy A, Picard F (August 2014). "Electrical stimulation of a small brain area reversibly disrupts consciousness". Epilepsy & Behavior. 37: 32–5. doi:10.1016/j.yebeh.2014.05.027. PMID 24967698. S2CID 8368944.
  24. ^ Xuei X, Dick D, Flury-Wetherill L, Tian HJ, Agrawal A, Bierut L, Goate A, Bucholz K, Schuckit M, Nurnberger J, Tischfield J, Kuperman S, Porjesz B, Begleiter H, Foroud T, Edenberg HJ (November 2006). "Association of the kappa-opioid system with alcohol dependence". Molecular Psychiatry. 11 (11): 1016–24. doi:10.1038/sj.mp.4001882. PMID 16924269.
  25. ^ a b Urbano M, Guerrero M, Rosen H, Roberts E (May 2014). "Antagonists of the kappa opioid receptor". Bioorganic & Medicinal Chemistry Letters. 24 (9): 2021–32. doi:10.1016/j.bmcl.2014.03.040. PMID 24690494.
  26. ^ a b Zan GY, Wang Q, Wang YJ, Liu Y, Hang A, Shu XH, Liu JG (September 2015). "Antagonism of κ opioid receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence". Behavioural Brain Research. 291: 334–41. doi:10.1016/j.bbr.2015.05.053. PMID 26049060. S2CID 32817749.
  27. ^ Pan ZZ (March 1998). "mu-Opposing actions of the kappa-opioid receptor". Trends in Pharmacological Sciences. 19 (3): 94–8. doi:10.1016/S0165-6147(98)01169-9. PMID 9584625.
  28. ^ Kaye AD, Vadivelu N, Urman RD (1 December 2014). Substance Abuse: Inpatient and Outpatient Management for Every Clinician. Springer. pp. 181–. ISBN 978-1-4939-1951-2.
  29. ^ Yamada K, Imai M, Yoshida S (January 1989). "Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist". European Journal of Pharmacology. 160 (2): 229–37. doi:10.1016/0014-2999(89)90495-0. PMID 2547626.
  30. ^ Zeynalov E, Nemoto M, Hurn PD, Koehler RC, Bhardwaj A (March 2006). "Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide". Journal of Cerebral Blood Flow and Metabolism. 26 (3): 414–20. doi:10.1038/sj.jcbfm.9600196. PMID 16049424.
  31. ^ Tortella FC, Robles L, Holaday JW (April 1986). "U50,488, a highly selective kappa opioid: anticonvulsant profile in rats". The Journal of Pharmacology and Experimental Therapeutics. 237 (1): 49–53. PMID 3007743.
  32. ^ Lawrence DM, Bidlack JM (September 1993). "The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein". The Journal of Pharmacology and Experimental Therapeutics. 266 (3): 1678–83. PMID 8103800.
  33. ^ Konkoy CS, Childers SR (January 1993). "Relationship between kappa 1 opioid receptor binding and inhibition of adenylyl cyclase in guinea pig brain membranes". Biochemical Pharmacology. 45 (1): 207–16. doi:10.1016/0006-2952(93)90394-C. PMID 8381004.
  34. ^ Schoffelmeer AN, Rice KC, Jacobson AE, Van Gelderen JG, Hogenboom F, Heijna MH, Mulder AH (September 1988). "Mu-, delta- and kappa-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate". European Journal of Pharmacology. 154 (2): 169–78. doi:10.1016/0014-2999(88)90094-5. PMID 2906610.
  35. ^ Henry DJ, Grandy DK, Lester HA, Davidson N, Chavkin C (March 1995). "Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes". Molecular Pharmacology. 47 (3): 551–7. PMID 7700253.
  36. ^ Tallent M, Dichter MA, Bell GI, Reisine T (December 1994). "The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells". Neuroscience. 63 (4): 1033–40. doi:10.1016/0306-4522(94)90570-3. PMID 7700508. S2CID 22003522.
  37. ^ Bohn LM, Belcheva MM, Coscia CJ (February 2000). "Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade". Journal of Neurochemistry. 74 (2): 564–73. doi:10.1046/j.1471-4159.2000.740564.x. PMC 2504523. PMID 10646507.
  38. ^ Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, Kiss A, Coscia CJ (July 2005). "Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes". The Journal of Biological Chemistry. 280 (30): 27662–9. doi:10.1074/jbc.M502593200. PMC 1400585. PMID 15944153.
  39. ^ Bruchas MR, Macey TA, Lowe JD, Chavkin C (June 2006). "Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes". The Journal of Biological Chemistry. 281 (26): 18081–9. doi:10.1074/jbc.M513640200. PMC 2096730. PMID 16648139.
  40. ^ a b Bruchas MR, Xu M, Chavkin C (September 2008). "Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2". NeuroReport. 19 (14): 1417–22. doi:10.1097/WNR.0b013e32830dd655. PMC 2641011. PMID 18766023.
  41. ^ Kam AY, Chan AS, Wong YH (July 2004). "Kappa-opioid receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells". The Journal of Pharmacology and Experimental Therapeutics. 310 (1): 301–10. doi:10.1124/jpet.104.065078. PMID 14996948. S2CID 39445016.
  42. ^ Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C (October 2007). "Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase". The Journal of Biological Chemistry. 282 (41): 29803–11. doi:10.1074/jbc.M705540200. PMC 2096775. PMID 17702750.
  43. ^ Pasternak GW (June 1980). "Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia". Proceedings of the National Academy of Sciences of the United States of America. 77 (6): 3691–4. Bibcode:1980PNAS...77.3691P. doi:10.1073/pnas.77.6.3691. PMC 349684. PMID 6251477.
  44. ^ Holtzman SG (February 1985). "Drug discrimination studies". Drug and Alcohol Dependence. 14 (3–4): 263–82. doi:10.1016/0376-8716(85)90061-4. PMID 2859972.
  45. ^ Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT (December 2007). "Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain". Pain. 132 (3): 289–300. doi:10.1016/j.pain.2007.03.022. PMID 17467904. S2CID 19872213.
  46. ^ a b White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL (January 2015). "The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo". The Journal of Pharmacology and Experimental Therapeutics. 352 (1): 98–109. doi:10.1124/jpet.114.216820. PMC 4279099. PMID 25320048.
  47. ^ Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, Liu-Chen LY (March 2008). "2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A". The Journal of Pharmacology and Experimental Therapeutics. 324 (3): 1073–83. doi:10.1124/jpet.107.132142. PMC 2519046. PMID 18089845.
  48. ^ Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA, Cohen BM, Béguin C (February 2008). "Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers". Bioorganic & Medicinal Chemistry. 16 (3): 1279–86. doi:10.1016/j.bmc.2007.10.067. PMC 2568987. PMID 17981041.
  49. ^ Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (April 2009). "Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats". Psychopharmacology. 203 (2): 203–11. doi:10.1007/s00213-008-1458-3. PMID 19153716.
  50. ^ Patrick GL (10 January 2013). An Introduction to Medicinal Chemistry. OUP Oxford. pp. 657–. ISBN 978-0-19-969739-7.
  51. ^ Nagase H (21 January 2011). Chemistry of Opioids. Springer. pp. 34, 48, 57–60. ISBN 978-3-642-18107-8.
  52. ^ Katavic PL, Lamb K, Navarro H, Prisinzano TE (August 2007). "Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships". Journal of Natural Products. 70 (8): 1278–82. doi:10.1021/np070194x. PMC 2265593. PMID 17685652.
  53. ^ a b Casal-Dominguez JJ, Furkert D, Ostovar M, Teintang L, Clark MJ, Traynor JR, Husbands SM, Bailey SJ (March 2014). "Characterization of BU09059: a novel potent selective κ-receptor antagonist". ACS Chemical Neuroscience. 5 (3): 177–84. doi:10.1021/cn4001507. PMC 3963132. PMID 24410326.
  54. ^ "CVL-354". adisinsight.springer.com. Retrieved 2 February 2023.
  55. ^ Hartung AM, Beutler JA, Navarro HA, Wiemer DF, Neighbors JD (February 2014). "Stilbenes as κ-selective, non-nitrogenous opioid receptor antagonists". Journal of Natural Products. 77 (2): 311–9. doi:10.1021/np4009046. PMC 3993902. PMID 24456556.
  56. ^ Galeotti N, Di Cesare Mannelli L, Mazzanti G, Bartolini A, Ghelardini C (April 2002). "Menthol: a natural analgesic compound". Neuroscience Letters. 322 (3): 145–8. doi:10.1016/S0304-3940(01)02527-7. PMID 11897159. S2CID 33979563.
  57. ^ Werkheiser JL, Rawls SM, Cowan A (October 2006). "Mu and kappa opioid receptor agonists antagonize icilin-induced wet-dog shaking in rats". European Journal of Pharmacology. 547 (1–3): 101–5. doi:10.1016/j.ejphar.2006.07.026. PMID 16945367.
  58. ^ Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ (January 2007). "Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 300–6. doi:10.1124/jpet.106.112417. PMID 17060493. S2CID 5555012.
  59. ^ Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (March 2004). "Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 1197–203. doi:10.1124/jpet.103.059394. PMID 14718611. S2CID 2398097.
  60. ^ Glick SD, Maisonneuve IS (May 1998). "Mechanisms of antiaddictive actions of ibogaine". Annals of the New York Academy of Sciences. 844 (1): 214–226. Bibcode:1998NYASA.844..214G. doi:10.1111/j.1749-6632.1998.tb08237.x. PMID 9668680. S2CID 11416176.
  61. ^ Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, et al. (2021-07-23). "Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Addiction States". bioRxiv: 2021.07.22.453441. doi:10.1101/2021.07.22.453441. S2CID 236436956.
  62. ^ Wold EA, Chen J, Cunningham KA, Zhou J (January 2019). "Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts". Journal of Medicinal Chemistry. 62 (1): 88–127. doi:10.1021/acs.jmedchem.8b00875. PMC 6556150. PMID 30106578. BMS-986187 (179), with a chemically novel core compared to previous BMS series, was discovered as an effective PAM at the DOR and at the κ-opioid receptor (KOR) rather than the MOR with an approximately 20-to 30-fold higher affinity in the allosteric ternary complex model.261
  63. ^ Livingston KE, Stanczyk MA, Burford NT, Alt A, Canals M, Traynor JR (February 2018). "Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors". Molecular Pharmacology. 93 (2): 157–167. doi:10.1124/mol.117.109561. PMC 5767684. PMID 29233847.
  64. ^ Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M, Nagase H, Suzuki T (October 2004). "Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence". Annals of the New York Academy of Sciences. 1025 (1): 404–13. Bibcode:2004NYASA1025..404H. doi:10.1196/annals.1316.050. PMID 15542743. S2CID 85031737.
  65. ^ Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ (July 2008). "Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users". Neuropharmacology. 55 (1): 41–6. doi:10.1016/j.neuropharm.2008.04.019. PMC 2577569. PMID 18538358.
  66. ^ Michaels CC, Holtzman SG (April 2008). "Early postnatal stress alters place conditioning to both mu- and kappa-opioid agonists". The Journal of Pharmacology and Experimental Therapeutics. 325 (1): 313–8. doi:10.1124/jpet.107.129908. PMID 18203949. S2CID 30383220.
  67. ^ Beardsley PM, Howard JL, Shelton KL, Carroll FI (November 2005). "Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats". Psychopharmacology. 183 (1): 118–26. doi:10.1007/s00213-005-0167-4. PMID 16184376. S2CID 31140425.
  68. ^ Redila VA, Chavkin C (September 2008). "Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system". Psychopharmacology. 200 (1): 59–70. doi:10.1007/s00213-008-1122-y. PMC 2680147. PMID 18575850.
  69. ^ Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE (November 2000). "Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors". Journal of Psychoactive Drugs. 32 (Suppl): i–iv, 1–112. doi:10.1080/02791072.2000.10736099. PMID 11280926. S2CID 22497665.
  70. ^ Stefański R, Ziółkowska B, Kuśmider M, Mierzejewski P, Wyszogrodzka E, Kołomańska P, Dziedzicka-Wasylewska M, Przewłocki R, Kostowski W (July 2007). "Active versus passive cocaine administration: differences in the neuroadaptive changes in the brain dopaminergic system". Brain Research. 1157: 1–10. doi:10.1016/j.brainres.2007.04.074. PMID 17544385. S2CID 42090922.
  71. ^ Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP (September 1998). "Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys". Synapse. 30 (1): 88–96. doi:10.1002/(SICI)1098-2396(199809)30:1<88::AID-SYN11>3.0.CO;2-L. PMID 9704885. S2CID 22569502.
  72. ^ D'Addario C, Di Benedetto M, Izenwasser S, Candeletti S, Romualdi P (January 2007). "Role of serotonin in the regulation of the dynorphinergic system by a kappa-opioid agonist and cocaine treatment in rat CNS". Neuroscience. 144 (1): 157–64. doi:10.1016/j.neuroscience.2006.09.008. PMID 17055175. S2CID 34243587.
  73. ^ Mash DC, Staley JK (June 1999). "D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims". Annals of the New York Academy of Sciences. 877 (1): 507–22. Bibcode:1999NYASA.877..507M. doi:10.1111/j.1749-6632.1999.tb09286.x. PMID 10415668. S2CID 25867468.
  74. ^ Schenk S, Partridge B, Shippenberg TS (June 1999). "U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking". Psychopharmacology. 144 (4): 339–46. doi:10.1007/s002130051016. PMID 10435406. S2CID 19726351.
  75. ^ Patkar AA, Mannelli P, Hill KP, Peindl K, Pae CU, Lee TH (August 2006). "Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence". Human Psychopharmacology. 21 (6): 367–75. doi:10.1002/hup.780. PMID 16915581. S2CID 21895907.
  76. ^ Butelman ER, Kreek MJ (July 2001). "kappa-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists". European Journal of Pharmacology. 423 (2–3): 243–9. doi:10.1016/S0014-2999(01)01121-9. PMID 11448491.
  77. ^ Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW, Weiss S (February 2007). "White matter plasticity and enhanced remyelination in the maternal CNS". The Journal of Neuroscience. 27 (8): 1812–23. doi:10.1523/JNEUROSCI.4441-06.2007. PMC 6673564. PMID 17314279.
  78. ^ McLaughlin JP, Marton-Popovici M, Chavkin C (July 2003). "Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses". The Journal of Neuroscience. 23 (13): 5674–83. doi:10.1523/JNEUROSCI.23-13-05674.2003. PMC 2104777. PMID 12843270.
  79. ^ McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C (June 2006). "Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system". Neuropsychopharmacology. 31 (6): 1241–8. doi:10.1038/sj.npp.1300872. PMC 2096774. PMID 16123746.
  80. ^ Koob GF (July 2008). "A role for brain stress systems in addiction". Neuron. 59 (1): 11–34. doi:10.1016/j.neuron.2008.06.012. PMC 2748830. PMID 18614026.
  81. ^ Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, Chavkin C (October 2007). "Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria". The Journal of Neuroscience. 27 (43): 11614–23. doi:10.1523/JNEUROSCI.3769-07.2007. PMC 2481272. PMID 17959804.
  82. ^ a b Banks ML (2020). "The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research". Substance Use Disorders. Handbook of Experimental Pharmacology. Vol. 258. pp. 147–165. doi:10.1007/164_2019_268. ISBN 978-3-030-33678-3. PMC 7756963. PMID 31463605.
  83. ^ a b c d Tejeda HA, Bonci A (June 2019). "Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders". Brain Research. 1713: 91–101. doi:10.1016/j.brainres.2018.09.023. PMID 30244022. S2CID 52339964.
  84. ^ Mitchell JM, Liang MT, Fields HL (November 2005). "A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats". Psychopharmacology. 182 (3): 384–92. doi:10.1007/s00213-005-0067-7. PMID 16001119. S2CID 38011973.
  85. ^ Walker BM, Koob GF (February 2008). "Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence". Neuropsychopharmacology. 33 (3): 643–52. doi:10.1038/sj.npp.1301438. PMC 2739278. PMID 17473837.
  86. ^ Xi ZX, Fuller SA, Stein EA (January 1998). "Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study". The Journal of Pharmacology and Experimental Therapeutics. 284 (1): 151–61. PMID 9435173.
  87. ^ Narita M, Khotib J, Suzuki M, Ozaki S, Yajima Y, Suzuki T (June 2003). "Heterologous mu-opioid receptor adaptation by repeated stimulation of kappa-opioid receptor: up-regulation of G-protein activation and antinociception". Journal of Neurochemistry. 85 (5): 1171–9. doi:10.1046/j.1471-4159.2003.01754.x. PMID 12753076. S2CID 26034314.
  88. ^ Maisonneuve IM, Archer S, Glick SD (November 1994). "U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats". Neuroscience Letters. 181 (1–2): 57–60. doi:10.1016/0304-3940(94)90559-2. PMID 7898771. S2CID 25258989.
  89. ^ Wee S, Koob GF (June 2010). "The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse". Psychopharmacology. 210 (2): 121–35. doi:10.1007/s00213-010-1825-8. PMC 2879894. PMID 20352414.
  90. ^ Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ (March 2018). "Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence". Neuropsychopharmacology. 43 (4): 928. doi:10.1038/npp.2017.245. PMC 5809793. PMID 29422497.
  91. ^ a b Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, et al. (May 2020). "A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia". Nature Medicine. 26 (5): 760–768. doi:10.1038/s41591-020-0806-7. PMC 9949770. PMID 32231295. S2CID 214704502.
  92. ^ a b Martinez D, Slifstein M, Matuskey D, Nabulsi N, Zheng MQ, Lin SF, et al. (September 2019). "Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study". Neuropsychopharmacology. 44 (10): 1720–1727. doi:10.1038/s41386-019-0398-4. PMC 6785004. PMID 31026862.
  93. ^ Farahbakhsh ZZ, Song K, Branthwaite HE, Erickson KR, Mukerjee S, Nolan SO, Siciliano CA (May 2023). "Systemic kappa opioid receptor antagonism accelerates reinforcement learning via augmentation of novelty processing in male mice". Neuropsychopharmacology. 48 (6): 857–868. doi:10.1038/s41386-023-01547-x. PMC 10156709. PMID 36804487.
  94. ^ Braden K, Castro DC (May 2023). "Kappa opioid receptors as modulators of novelty processing". Neuropsychopharmacology. 48 (6): 848–849. doi:10.1038/s41386-023-01561-z. PMC 10156680. PMID 36922627.
  95. ^ Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, et al. (September 2020). "Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)". Neuropsychopharmacology. 45 (10): 1656–1663. doi:10.1038/s41386-020-0738-4. PMC 7419512. PMID 32544925.
  96. ^ Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, et al. (May 2020). "A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia". Nature Medicine. 26 (5): 760–768. doi:10.1038/s41591-020-0806-7. PMC 9949770. PMID 32231295.
  97. ^ Huang P, Steplock D, Weinman EJ, Hall RA, Ding Z, Li J, Wang Y, Liu-Chen LY (June 2004). "kappa Opioid receptor interacts with Na(+)/H(+)-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na(+)/H(+) exchange independent of G(i)/G(o) proteins". The Journal of Biological Chemistry. 279 (24): 25002–9. doi:10.1074/jbc.M313366200. PMID 15070904.
  98. ^ Li JG, Chen C, Liu-Chen LY (July 2002). "Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate". The Journal of Biological Chemistry. 277 (30): 27545–52. doi:10.1074/jbc.M200058200. PMID 12004055.
  99. ^ Li JG, Haines DS, Liu-Chen LY (April 2008). "Agonist-promoted Lys63-linked polyubiquitination of the human kappa-opioid receptor is involved in receptor down-regulation". Molecular Pharmacology. 73 (4): 1319–30. doi:10.1124/mol.107.042846. PMC 3489932. PMID 18212250.
  100. ^ Maraschin JC, Almeida CB, Rangel MP, Roncon CM, Sestile CC, Zangrossi H, Graeff FG, Audi EA (June 2017). "Participation of dorsal periaqueductal gray 5-HT1A receptors in the panicolytic-like effect of the κ-opioid receptor antagonist Nor-BNI". Behavioural Brain Research. 327: 75–82. doi:10.1016/j.bbr.2017.03.033. PMID 28347824. S2CID 22465963.
  101. ^ Gross JD, Kaski SW, Schmidt KT, Cogan ES, Boyt KM, Wix K, et al. (September 2019). "Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior". Neuropsychopharmacology. 44 (10): 1728–1741. doi:10.1038/s41386-019-0423-7. PMC 6785087. PMID 31141817.
Kembali kehalaman sebelumnya